iCellate Medical receives first patient samples in two new clinical studies
Stockholm, Sweden – October 3, 2023 – iCellate continues validation of its circulating tumor cell (CTC) platform CellMate® across various cancer indications. This week we anticipate including the first patient samples in two new studies, a prostate study in collaboration with Capio Urology Center in Liljeholmen, Sweden and a pancreatic study together with Karolinska University Hospital in Huddinge.Clinical evidence is currently in focus for iCellate, i.e. more data to support the commercial efforts in establishing CellMate® as a companion diagnostic in pharma development projects and using